LEADER 04359nam 2200577 a 450 001 9910437832103321 005 20200520144314.0 010 $a3-642-36648-1 024 7 $a10.1007/978-3-642-36648-2 035 $a(CKB)2670000000371169 035 $a(EBL)1316886 035 $a(SSID)ssj0000894464 035 $a(PQKBManifestationID)11475624 035 $a(PQKBTitleCode)TC0000894464 035 $a(PQKBWorkID)10839802 035 $a(PQKB)10355681 035 $a(DE-He213)978-3-642-36648-2 035 $a(MiAaPQ)EBC1316886 035 $a(PPN)170491064 035 $a(EXLCZ)992670000000371169 100 $a20130603d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aProgrammed cells from basic neuroscience to therapy /$fFred H. Gage, Yves Christen, editors 205 $a1st ed. 2013. 210 $aHeidelberg $cSpringer$dc2013 215 $a1 online resource (137 p.) 225 1 $aResearch and perspectives in neurosciences,$x0945-6082 300 $aDescription based upon print version of record. 311 $a3-642-36647-3 320 $aIncludes bibliographical references and index. 327 $aNuclear reprogramming by eggs and oocytes and eventual prospects of cell replacement therapy.- iPS technology and disease research: issues to be resolved -- ES and iPS cells as tools for modeling human aging .-Characterizing neural circuitry with programmed human neurons.- Direct conversion of fibroblasts to neuronal cells -- Human pluripotent stem cells as tools for modelling neurodegeneration.- From Rett syndrome to classical autism: modeling autism spectrum disorders using human neurons.- Testing evolutionary principles in a dish using embryonic stem cells: the example of the Huntington's Disease gene.- Using stem cells to discover therapeutic targets in ALS and SMA .- Using stem cells to understand and treat Alzheimer's disease.- Using pluripotent stem cells to decipher mechanisms and identify treatments for diseases that affect the brain.- Modeling neural development and disease in human pluripotent stem cells -- Subject index. 330 $aThe recent advances in Programming Somatic Cell (PSC) including induced Pluripotent Stem Cells (iPS) and Induced Neuronal phenotypes (iN), has changed the experimental landscape and opened new possibilities. The advances in PSC have provided an important tool for the study of human neuronal function as well as neurodegenerative and neurodevelopmental diseases in live human neurons in a controlled environment. For example, reprogramming cells from patients with neurological diseases allows the study of molecular pathways particular to specific subtypes of neurons such as dopaminergic neurons in Parkinson?s Disease, Motor neurons for Amyolateral Sclerosis or myelin for Multiple Sclerosis. In addition, because PSC technology allows for the study of human neurons during development, disease-specific pathways can be investigated prior to and during disease onset. Detecting disease-specific molecular signatures in live human brain cells, opens possibilities for early intervention therapies and new diagnostic tools. Importantly, it is now feasible to obtain gene expression profiles from neurons that capture the genetic uniqueness of each patient. Importantly, once the neurological neural phenotype is detected in vitro, the so-called ?disease-in-a-dish? approach allows for the screening of drugs that can ameliorate the disease-specific phenotype. New therapeutic drugs could either act on generalized pathways in all patients or be patient-specific and used in a personalized medicine approach. However, there are a number of pressing issues that need to be addressed and resolved before PSC technology can be extensively used for clinically relevant modeling of neurological diseases. 410 0$aResearch and perspectives in neurosciences. 606 $aStem cells 606 $aNeurons 615 0$aStem cells. 615 0$aNeurons. 676 $a612.8 701 $aGage$b Fred H$01754551 701 $aChristen$b Yves$0155886 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437832103321 996 $aProgrammed cells from basic neuroscience to therapy$94190981 997 $aUNINA